This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Pfizer (PFE) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.
Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive second-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco
by Zacks Equity Research
Eli Lilly (LLY) tops estimates for both earnings and sales in the second quarter and raises guidance for 2018. It will divest its Elanco unit into a new public company. Stock up in pre-market trading.
Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Healthcare ETFs to Buy on Solid Q2 Earnings Expectations
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy
by Zacks Equity Research
Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
by Zacks Equity Research
J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.
Roche's Tecentriq Met Primary Goal in First-Line NSCLC Study
by Zacks Equity Research
Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS).
J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.
Does the $4.7 Billion Talc Verdict Spell Trouble for J&J?
by David Borun
After a jury awards cancer victims a huge payout, is there more trouble ahead?
Amgen Resubmits BLA to FDA for Osteoporosis Candidate Evenity
by Zacks Equity Research
Amgen Inc. (AMGN) and its partner UCB announce the resubmission of the BLA to the FDA for Evenity to treat osteoporosis in postmenopausal women and in men at increased risk of fracture.
Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize
by Swarup Gupta
The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.
Pfizer (PFE) to Reorganize Business Into Three New Units
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up?
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales in the past three quarters is likely to continue in Q2.
Bristol-Myers' Combo Drugs Get FDA Nod for Colorectal Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo in combination with its Yervoy received the FDA approval to treat patients with metastatic colorectal cancer (mCRC) that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
by Zacks Equity Research
The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.
Pfizer to Defer Price Increases After Discussion With Trump
by Zacks Equity Research
Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.
Drug Pricing in Focus Again as Trump Tweet Slams Pfizer
by Kinjel Shah
In a tweet, Trump says Pfizer and other U.S. drugmakers should be "ashamed" that they have raised drug prices for "no reason".
Pharma Stock Roundup: NVS to Divest Eye Care Unit, CHMP Gives Nod to Several Drugs
by Zacks Equity Research
Novartis (NVS) intends to spin off its Alcon eye care division. The CHMP gives positive opinion recommending marketing approval to several drugs.
Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review
by Swarup Gupta
The Dow traverses a holiday-shortened week during which trading volumes remain low.
Bristol-Myers' Sprycel Gets EC Approval for Label Expansion
by Zacks Equity Research
Bristol-Myers (BMY) receives EC approval for the label expansion of Sprycel for the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in patients aged one to 18 years.
AstraZeneca's Two New Cancer Drugs Get Approval in Japan
by Zacks Equity Research
AstraZeneca gets approval in Japan for two new cancer drugs. These include Lynparza for a breast cancer indication and Imfinzi for an early-stage lung cancer indication.
Merck's Keytruda Gets Priority Review in Difficult Lung Cancer
by Zacks Equity Research
Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.